Shire Says Vpriv Is A Viable Option for Cerezyme Patients; Gets PDUFA For Firazyr
This article was originally published in The Pink Sheet Daily
Executive Summary
Firazyr could enjoy a dosing advantage over other HAE drugs currently on the U.S. marketplace if it can get approval from FDA.
You may also be interested in...
Despite Rival's Supply Problems, No Guarantee That Shire Will Re-File Replagal In U.S.
Human Genetic Therapies division President Gregoire also says self-administration should be a key point of differentiation for Firazyr in the HAE market.
Despite Rival's Supply Problems, No Guarantee That Shire Will Re-File Replagal In U.S.
Human Genetic Therapies division President Gregoire also says self-administration should be a key point of differentiation for Firazyr in the HAE market.
Is Europe's HAE Market Big Enough To Sustain All The Competitors?
As more companies of all sizes embrace rare diseases – lured in part by supposed lower regulatory and reimbursement hurdles – some niche markets are beginning to look rather busy.